December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Biotech investors’ forecast: Where will early-stage investment go in 2025?

Edition

Biotech investors’ forecast: Where will early-stage investment go in 2025?

It’s time for an end-of-year review of biotech investing: expert investors share the trends they saw for 2024 and the deals that made a difference. Was 2024 a good year for early-stage investing? Where did larger funds’ money go? What was the geographical diversity of early-stage deals?  What’s under and on the radar? What can we expect in 2025? Which therapeutic areas will attract or increase VC interest?

Moderator: Philippe Monteyne, Partner, Aliath Bioventures

Florian Denis

Investment Director
Elaia Partners

Anela Vukoja

COO
Apollo Health Ventures

Frank Hensel

Principal
High-Tech Gründerfonds
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.